Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Lupus patients who don't take enough hydroxychloroquine (HCQ) may be putting their hearts at risk. A new study found that low HCQ blood levels and poor long-term adherence are linked to significantly higher risk of atherosclerotic cardiovascular disease (ASCVD) in people with systemic lupus erythematosus (SLE). Experts say monitoring both blood levels and refill patterns could be a game-changer for managing heart risk in lupus patients.
Hydroxychloroquine (HCQ) is the go-to medication for managing systemic lupus erythematosus (SLE), and for good reason — it reduces disease flares, limits organ damage, and has long been associated with cardiovascular protection. But a new prospective study published in Arthritis Care & Research suggests that how well patients stick to their HCQ regimen matters a lot more than previously appreciated when it comes to heart health.
Researchers from Yale analyzed data from 248 adult SLE patients on HCQ and found that those with consistently low blood levels or poor long-term adherence faced meaningfully higher predicted risk for atherosclerotic cardiovascular disease (ASCVD). Patients who either sustained low HCQ markers or dropped from high to low markers over the course of a year showed the greatest cardiovascular risk.
By the Numbers:
Why it matters: For clinicians managing lupus, this study makes a strong case for routinely monitoring both HCQ blood levels and refill-based adherence metrics. Together, these tools can help identify patients at elevated cardiovascular risk before problems arise — and guide more personalized counseling on the long-term benefits of staying on therapy.
